Integrilin (Merck Sharp & Dohme Corp.)
Welcome to the PulseAid listing for the Integrilin drug offered from Merck Sharp & Dohme Corp.. This Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Merck Sharp & Dohme Corp. |
NON-PROPRIETARY NAME: | Eptifibatide |
SUBSTANCE NAME: | EPTIFIBATIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Decreased Platelet Aggregation [PE],Platelet Aggregation Inhibitor [EPC] |
ROUTE: | INTRAVENOUS |
DOSAGE FORM: | INJECTION, SOLUTION |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-01-23 |
END MARKETING DATE: | 0000-00-00 |
Integrilin HUMAN PRESCRIPTION DRUG Details:
Item Description | Integrilin from Merck Sharp & Dohme Corp. |
LABELER NAME: | Merck Sharp & Dohme Corp. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.75(mg/mL) |
START MARKETING DATE: | 2015-01-23 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0085-1136_09400257-b29a-4eb6-972b-25b966979db5 |
PRODUCT NDC: | 0085-1136 |
APPLICATION NUMBER: | NDA020718 |
Other EPTIFIBATIDE Pharmaceutical Manufacturers / Labelers: